Guidelines for pharmacokinetic and pharmacodynamic studies in early phase clinical trials
ثبت نشده
چکیده
Introduction The Pharmacodynamic/ pharmacokinetic Technologies Advisory Committee (PTAC) of Cancer Research UK has the objective of increasing the extent of mechanistic and hypothesis testing in early phase clinical trials. PTAC reviews all applications submitted to the New Agents Committee (NAC) and with expertise in PET, MRI and MRS as well as many of the other currently emerging technologies, provides advice on the potential use of these techniques to add value to the development of new anticancer agents.
منابع مشابه
The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials.
Although the concept of a phase 0 trial is a relatively new one, there has been a slowly increasing trend toward basing early clinical trial designs on pharmacokinetic and pharmacodynamic end points that has been developing over many years. This article will review the early cancer trial methodologies and the various techniques that have been used to refine them. Several illustrative examples w...
متن کاملImproved power for TB Phase IIa trials using a model-based pharmacokinetic-pharmacodynamic approach compared with commonly used analysis methods.
Background The demand for new anti-TB drugs is high, but development programmes are long and costly. Consequently there is a need for new strategies capable of accelerating this process. Objectives To explore the power to find statistically significant drug effects using a model-based pharmacokinetic-pharmacodynamic approach in comparison with the methods commonly used for analysing TB Phase ...
متن کاملProduction, Quality Control and Pharmacokinetic Studies of 177Lu-EDTMP for Human Bone Pain Palliation Therapy Trials
Developing new bone pain palliation agents is a mandate in handling end-stage cancer patients around the world. Possibly, Lu-177 ethylenediaminetetramethylene phosphonic acid (177Lu-EDTMP) is a therapeutic agent which can be widely used in bone palliation therapy. In this study, 177Lu-EDTMP complex was prepared successfully using synthesized EDTMP ligand and 177LuCl3. Lu-177 chloride was obt...
متن کاملPharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection
BACKGROUND AND OBJECTIVES Filgotinib (GLPG0634) is a selective inhibitor of Janus kinase 1 (JAK1) currently in development for the treatment of rheumatoid arthritis and Crohn's disease. While less selective JAK inhibitors have shown long-term efficacy in treating inflammatory conditions, this was accompanied by dose-limiting side effects. Here, we describe the pharmacokinetics of filgotinib and...
متن کاملدرماتولوژی مبتنی بر شواهد: گزارش درست مقایسهی پیامدها در کارآزماییهای بالینی
According to evidence-based medicine, randomized controlled clinical trials are a group of research designs which provides the highest level of clinical evidence, particularly regarding therapeutic or preventive interventions. Considering the dramatic increase in the number of published clinical trials in medical journals, the readership need to have knowledge about the problems that may occur ...
متن کامل